Does Amerigroup Cover Ozempic?

What Is Amerigroup and Which Plans Does It Administer?

Amerigroup is a managed care organization owned by Elevance Health (formerly Anthem). It operates Medicaid managed care plans in roughly 14 states, including Texas, Georgia, Florida, Nevada, Tennessee, and Maryland, and it administers Medicare Advantage plans in several of those same states. Because Amerigroup contracts separately with each state's Medicaid agency, formulary rules for Ozempic are not uniform across all plans. A member in Georgia may face different step-therapy requirements than a member in Texas, even though both plans carry the Amerigroup name.

Ozempic (semaglutide, Novo Nordisk) received FDA approval in December 2017 for glycemic control in adults with type 2 diabetes, with a secondary cardiovascular risk-reduction indication added in 2020 based on the SUSTAIN-6 trial (N=3,297). That cardiovascular outcome data is relevant to coverage arguments because it positions Ozempic not only as a glucose-lowering agent but as a drug with demonstrated mortality-adjacent benefit in patients with established cardiovascular disease.

Because Medicaid is jointly funded by federal and state governments, the Centers for Medicare and Medicaid Services (CMS) requires state Medicaid programs to cover all FDA-approved drugs from manufacturers who participate in the Medicaid Drug Rebate Program, which Novo Nordisk does. However, states and their managed care contractors like Amerigroup retain the authority to set prior authorization requirements, quantity limits, and step-therapy protocols as long as those measures do not prevent access to medically necessary care. That legal framework is why coverage exists on paper but can feel difficult to access in practice.

How Amerigroup's Formulary Places Ozempic

Amerigroup places Ozempic on a non-preferred specialty tier in most of its state Medicaid formularies. Non-preferred specialty placement means cost-sharing is higher and prior authorization is mandatory before the pharmacy will dispense the drug. On Medicare Advantage plans, Ozempic typically lands on Tier 3 or Tier 4 of a five-tier formulary, where copays range from $45 to $100 per fill depending on the plan year's Summary of Evidence of Coverage document.

The formulary tier also matters for step therapy. Most Amerigroup Medicaid plans require at least one of the following before Ozempic is approved:

• A documented 90-day trial of metformin (unless contraindicated due to eGFR <30 mL/min/1.73m², gastrointestinal intolerance, or lactic acidosis risk).
• An HbA1c of 7.5% or higher at the time of the prior authorization request.
• Documentation that a sulfonylurea was tried and either failed or was contraindicated.

Some state plans add a requirement that the prescribing physician be an endocrinologist or have documented diabetes management experience. This requirement has been challenged legally in several states as creating a specialist bottleneck that delays medically necessary care, and CMS guidance from 2023 reinforced that step-therapy protocols must include a timely exception process (CMS Final Rule CMS-4201-F).

Prior Authorization: The Step-by-Step Process for Amerigroup Members

Getting Ozempic approved through Amerigroup requires a structured PA submission. Rushing the process or submitting incomplete documentation is the single most common reason approvals are delayed or denied outright.

Step 1. Confirm the correct diagnosis code. The PA form must include an ICD-10 code for type 2 diabetes, typically E11.65 (type 2 diabetes with hyperglycemia) or E11.9 (type 2 diabetes without complications). Using E66 (obesity) as the primary code when the actual goal is weight loss will trigger an automatic denial on most plans because Amerigroup Medicaid does not cover GLP-1 agents for obesity without an explicit obesity management carve-in.

Step 2. Gather supporting lab documentation. A recent HbA1c result (within 90 days on most plans) must accompany the request. The American Diabetes Association's 2024 Standards of Care define adequate glycemic control as HbA1c <7.0% for most non-pregnant adults, so demonstrating that the patient remains above target despite existing therapy is key clinical evidence.

Step 3. Document prior therapy. A pharmacy claims history showing metformin dispensing, or a clinician letter explaining why metformin was contraindicated, must be included. Vague language like "patient did not tolerate metformin" is insufficient; specifying "patient experienced grade 3 GI toxicity requiring emergency department visit on [date]" carries far more weight.

Step 4. Submit through Amerigroup's provider portal or by fax. Most Amerigroup states accept PA submissions through Availity or the state-specific Amerigroup provider portal. Fax remains an option but adds 24 to 48 hours of processing delay. Standard PA decisions are required within 3 business days under Medicaid managed care regulations; urgent requests tied to a documented clinical urgency must be decided within 72 hours.

Step 5. Track the decision and respond quickly. If additional information is requested (a "pend" notice), the prescriber typically has 14 calendar days to respond before the request is administratively closed. Missing that window means restarting the process from scratch.

Does Amerigroup Cover Ozempic for Weight Loss?

The short answer is: rarely, and only in specific states with an approved obesity treatment benefit.

Standard Medicaid does not mandate coverage of anti-obesity medications. As of early 2025, the Biden administration proposed a rule that would require Medicaid to cover anti-obesity drugs including GLP-1 agents for obesity, but that rule had not been finalized or implemented as of this article's publication date. The proposed CMS rule on anti-obesity medication coverage is available for reference.

Wegovy, the 2.4 mg semaglutide formulation approved specifically for chronic weight management in adults with BMI of 30 or higher (or BMI >27 with at least one weight-related comorbidity), is even less likely to be covered by Amerigroup Medicaid than Ozempic. STEP-1 (N=1,961) demonstrated a mean 14.9% body weight reduction with semaglutide 2.4 mg at 68 weeks compared with 2.4% placebo (Wilding et al., NEJM 2021), a result that has driven intense patient demand, but strong clinical data has not translated to Medicaid coverage in most states.

For Medicare Advantage members enrolled through Amerigroup, the Inflation Reduction Act did not include GLP-1 agents for obesity in the negotiated drug price list, and standalone Part D plans are prohibited by statute from covering drugs used "for anorexia, weight loss, or weight gain" except when prescribed for a different covered indication. This prohibition is codified in 42 U.S.C. § 1395w-102(e)(2)(A) and remains in effect unless Congress acts to amend it.

Patients who have both type 2 diabetes and obesity may have a pathway: if the prescribing physician documents Ozempic as medically necessary for glycemic control, the weight benefit is incidental and the diabetes indication can support coverage. This is a legitimate and commonly used clinical approach, not a workaround.

What to Do If Amerigroup Denies Ozempic Coverage

A denial is not a final answer. Amerigroup members have at least three formal recourse levels under federal Medicaid managed care regulations at 42 CFR Part 438.

Level 1: Internal Appeal. The member or prescribing physician may file an internal appeal within 60 days of the denial notice. The appeal should include a detailed clinical letter from the physician explaining why Ozempic is medically necessary for this specific patient, citing the patient's HbA1c trajectory, cardiovascular risk profile, and any contraindications to alternatives. Attaching peer-reviewed literature is optional but often persuasive. SUSTAIN-6 demonstrated a 26% relative risk reduction in nonfatal myocardial infarction and stroke with semaglutide in patients with established cardiovascular disease (Marso et al., NEJM 2016), which is relevant clinical evidence for high-risk patients.

Level 2: State Fair Hearing. If the internal appeal is denied, the member may request a state fair hearing administered by the state Medicaid agency, not Amerigroup. This is an independent administrative hearing where a neutral hearing officer reviews whether the managed care plan's denial was consistent with state Medicaid policy. Request deadlines vary by state but are typically 120 days from the internal appeal denial.

Level 3: External Independent Review. Most states require that Medicaid managed care organizations offer an external independent review by a third-party clinical reviewer. This review is binding on Amerigroup in most state contracts.

The HealthRX clinical team recommends that prescribers use a structured PA letter template that addresses each specific PA criterion listed in the plan's published criteria. Amerigroup publishes its clinical criteria documents on its provider website; the criteria for GLP-1 receptor agonists are typically titled "Antidiabetic Agents, GLP-1 Receptor Agonists" and are updated annually. Referencing the plan's own criteria language in the PA letter closes the evaluative loop and reduces discretionary denial.

Alternatives Amerigroup May Cover More Easily

If Ozempic PA is denied or delayed, other GLP-1 or diabetes medications may be accessible at lower prior authorization barriers on Amerigroup formularies.

Trulicity (dulaglutide). Once-weekly GLP-1 receptor agonist. The REWIND trial (N=9,901) showed a 12% relative risk reduction in major adverse cardiovascular events in patients with or at risk for cardiovascular disease (Gerstein et al., Lancet 2019). Dulaglutide is often on a preferred specialty tier for Amerigroup plans where semaglutide is non-preferred, which means lower cost-sharing and a less demanding PA process.

Victoza (liraglutide 1.2 mg / 1.8 mg). Daily GLP-1 injection. LEADER (N=9,340) demonstrated a 13% relative risk reduction in the primary MACE endpoint in patients with type 2 diabetes and high cardiovascular risk (Marso et al., NEJM 2016). Liraglutide has been on the Medicaid formulary longer than semaglutide and may face less restrictive step therapy in some Amerigroup state contracts.

Jardiance (empagliflozin). An SGLT-2 inhibitor rather than a GLP-1 agent, but frequently covered at preferred tier by Amerigroup for patients with type 2 diabetes and cardiovascular disease. The EMPA-REG OUTCOME trial (N=7,020) showed a 38% relative risk reduction in cardiovascular death (Zinman et al., NEJM 2015). For patients who need glycemic control plus cardiovascular protection and cannot get Ozempic approved, empagliflozin is a clinically defensible and more accessible option.

Metformin extended-release. Available generic, no PA required, covered on all Amerigroup Medicaid formularies. For patients who have not yet tried metformin, starting here is both medically appropriate and strategically necessary for building the step-therapy documentation required for future Ozempic approval.

How Amerigroup's Coverage Compares to Other Medicaid Managed Care Plans

Amerigroup's GLP-1 coverage policies are broadly similar to those of other large Medicaid managed care organizations such as Molina Healthcare, Centene (WellCare), and UnitedHealthcare Community Plan. All of them place GLP-1 agents on specialty tiers with mandatory prior authorization for diabetes indications and largely exclude them for obesity alone.

The key differentiator between plans at the state level is the step-therapy depth. Texas Medicaid, administered partly through Amerigroup, historically required two prior drug failures before approving a GLP-1 agent. Georgia Medicaid required only metformin trial documentation as of the most recent formulary review. Members should request their specific plan's "clinical authorization criteria" document, which Amerigroup is required to make available to enrolled members and providers under 42 CFR 438.10.

The CMS Medicaid Managed Care final rule prohibits managed care plans from applying prior authorization standards that are more restrictive than the fee-for-service Medicaid program in the same state. If a state's fee-for-service Medicaid covers Ozempic with a single prior authorization criterion, Amerigroup cannot add additional barriers beyond that baseline.

Practical Tips for Patients and Prescribers

Getting Ozempic covered through Amerigroup is achievable with systematic preparation. The following approach consistently produces better outcomes than ad hoc submissions.

For patients: Call Amerigroup member services (the number is on the back of the insurance card) before the prescription is written and ask specifically whether Ozempic is on the formulary for your plan and state, what PA criteria apply, and whether a preferred GLP-1 alternative exists. Getting these three data points in a single phone call prevents weeks of back-and-forth. Document the call date, the representative's name, and the reference number.

For prescribers: Submitting a PA with incomplete clinical documentation accounts for the majority of initial denials. The American Association of Clinical Endocrinology (AACE) 2023 Diabetes Management Algorithm recommends GLP-1 receptor agonists as preferred second-line agents after metformin in patients with type 2 diabetes and established atherosclerotic cardiovascular disease or high cardiovascular risk. Citing that guideline recommendation directly in the PA letter aligns the clinical rationale with a recognized national standard.

For appeals: The prescribing physician's peer-to-peer review call with the Amerigroup medical director is one of the highest-yield actions available. During a peer-to-peer, the treating physician can present case-specific nuances that a written PA form cannot capture. Peer-to-peer review requests must typically be made within 5 business days of the initial denial.

The Cost of Ozempic Without Coverage

A single 1 mg/dose Ozempic pen (4 doses, covering four weeks) carries a list price of approximately $935 to $1,050 at major U.S. pharmacies as of January 2025. The Novo Nordisk savings card program can reduce this to $25 per month for commercially insured patients, but the savings card is explicitly prohibited for use by patients enrolled in any federal or state government insurance program, including Medicaid and Medicare. This means Amerigroup Medicaid members who are denied coverage have no manufacturer assistance available.

Patient assistance programs through Novo Nordisk (the NovoCare Patient Assistance Program) can provide free Ozempic to uninsured or underinsured patients who meet income criteria, typically at or below 400% of the federal poverty level. Enrollment takes 4 to 6 weeks and requires annual recertification. The program is available at novo nordisk's patient assistance page, though patients should confirm current eligibility requirements directly with NovoCare.

State pharmaceutical assistance programs (SPAPs) in states like New Jersey and Pennsylvania may also bridge the cost gap for dual-eligible members who have both Medicaid and Medicare. Coverage details vary significantly by state.